Tuberous sclerosis and fulminant lupus in a young woman. - Wikidata - wikimedia - TriplyDB

Tuberous sclerosis and fulminant lupus in a young woman.

Tuberous sclerosis and fulminant lupus in a young woman.

http://www.wikidata.org/entity/Q33664866

about

mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging A case of systemic lupus erythematosus with multiple nodules in the bilateral lungs and vertebrae.Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.Tsc1 expression by dendritic cells is required to preserve T-cell homeostasis and response.Immunometabolism in systemic lupus erythematosus.Coexistence of systemic lupus erythematosus, tuberous sclerosis and aggressive natural killer-cell leukaemia: coincidence or correlated?Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy.Coexistence of SLE, tuberous sclerosis and aggressive natural killer-cell leukaemia: Coincidence or correlated?Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.

P2860

Q28081442-1D300CE5-C42D-4610-9750-D5F4FEECDC63 Q37296496-8772FACD-5D57-445C-8C9A-8C8C8A25A5A1 Q37649641-8022D5F2-3AD8-4983-AC80-1AF10FF2531C Q37649687-61C14220-2FC7-4AC2-9093-5676A9DBB957 Q37744972-782C38A1-4392-41D0-87F5-D3D529F10A61 Q39209701-B664D2F8-0AB4-4563-8538-25DB8F070E79 Q40766488-D85D78CE-1B75-4E47-A410-7360B15422E2 Q50068095-28AC1E5F-961B-4B66-92C3-668DD611EB1F Q54518611-A05C7A2D-1FFD-406F-9A63-AD5D76063843 Q55163735-844A1911-69EA-46C3-8C51-E7EF0125AB76

P2860

Tuberous sclerosis and fulminant lupus in a young woman.

http://www.wikidata.org/entity/Q33664866

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Tuberous sclerosis and fulminant lupus in a young woman.

@ast

Tuberous sclerosis and fulminant lupus in a young woman.

@en

type

label

Tuberous sclerosis and fulminant lupus in a young woman.

@ast

Tuberous sclerosis and fulminant lupus in a young woman.

@en

prefLabel

Tuberous sclerosis and fulminant lupus in a young woman.

@ast

Tuberous sclerosis and fulminant lupus in a young woman.

@en

P1433

Q33664866-298E10BD-0FDC-4973-8218-96D82E091464

P1476

Q33664866-E1A68F69-132F-4FED-B3FE-91D8C1D9FB63

P2093

Q33664866-9918563F-FB32-4D20-A202-686BAF9D1AB6

Q33664866-A1CA589D-58A4-47DD-BD1A-B5968C254B0E

Q33664866-F6DC7F54-DA76-41FC-A286-AB077698B62A

P2860

Q33664866-08D54DB3-A73B-4F2D-986F-637E5A749105

Q33664866-10A0780A-5758-42A4-BA5A-6882A7A50869

Q33664866-11AA9796-2FA9-4474-9988-2D2943F0ABE8

Q33664866-2BAA4D28-645E-4F4C-BF34-5F1FE404687B

Q33664866-44EC1804-EC67-41C6-8203-98DE2E0F83F2

Q33664866-4A0EB430-114F-4FE7-A717-BBE54C9B9B9E

Q33664866-531B16A0-4676-4DC2-B84D-27406FF3C444

Q33664866-9626988A-C08F-47A5-ACC5-F7E45A7C02AB

Q33664866-A48B3D3E-9FDD-4AC7-842B-EF0C3F6ABE86

Q33664866-DAF9A796-2DA7-4E3B-A5BB-5EE93334D66E

P304

Q33664866-24597711-8A4D-4EAD-8F05-F92E069DEBB5

P31

Q33664866-AF5888C9-FCE2-49F9-BACA-5154FBB07F03

P356

Q33664866-5690D615-B56F-4F79-93EE-967D88A101AC

P433

Q33664866-2323C436-838B-459C-A22A-3785B8F883B9

P478

Q33664866-8EA27D62-92F6-44E1-A607-13D89954854E

P50

Q33664866-EFFD6DEE-E4BF-49A1-B3B3-642E3762D979

Q33664866-F3E81B2B-DF63-471B-BC57-93BBA4424123

P577

Q33664866-275D4DEF-44AC-4FA6-BC48-76211705A239

P698

Q33664866-A09250C9-AE20-43EF-B82B-10D56C416499

P932

Q33664866-4EB6AE3B-856F-42EC-AC2D-1814129E42E4

P356

RHU.0B013E318289C033

P1433

Journal of Clinical Rheumatology

P1476

Tuberous sclerosis and fulminant lupus in a young woman

@en

P2093

Mark Birkenbach

http://www.w3.org/2001/XMLSchema#string

Philip L Cohen

http://www.w3.org/2001/XMLSchema#string

Tiffany Caza

http://www.w3.org/2001/XMLSchema#string

P2860

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus.

mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?

Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation

Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway.

Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis.

Apoptosis and mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus.

Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.

Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice.

PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus.

P304

134-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/RHU.0B013E318289C033

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23519178

http://www.w3.org/2001/XMLSchema#string

P932

4034128

http://www.w3.org/2001/XMLSchema#string